Table 3 |
|||
| Frequency of immunohistochemical expression of the examined biomarkers in nasopharyngeal carcinoma (sorted from the most frequently expressed to the least frequently ones) | |||
| Biomarker | No of Cases | Positive (%) | Negative (%) |
| Multi-Cytokeratin | 103 | 102 (99) | 1 (1) |
| COX-2 | 94 | 90 (95.7) | 4 (4.3) |
| P-cadherin | 97 | 92 (94.8) | 5 (5.2) |
| EBER | 101 | 94 (93.1) | 7 (6.9) |
| Phospho-GSK-3βSer9 | 100 | 92 (92) | 8 (8) |
| Fascin-1 | 96 | 88 (91.7) | 8 (8.3) |
| E-cadherin | 94 | 83 (88.3) | 11 (11.7) |
| p63 | 94 | 83 (88.3) | 11 (11.7) |
| EGFR | 95 | 83 (87.4) | 12 (12.6) |
| p53 | 95 | 82 (86.3) | 13 (13.7) |
| Phospho-AKTSer473 | 96 | 79 (82.3) | 17 (17.7) |
| Ki67 | 100 | 78 (78) | 22 (22) |
| ERCC1 | 105 | 78 (74.3) | 27 (25.7) |
| MAPT (Tau) | 104 | 74 (71.2) | 30 (28.8) |
| VEGF-C | 100 | 64 (64) | 36 (36) |
| Phospho-p44/42 MAPKThr202/Tyr204 | 95 | 60 (63.2) | 35 (36.8) |
| PTEN | 102 | 64 (62.7) | 38 (37.3) |
| VEGFR-3 | 101 | 60 (59.4) | 41 (40.6) |
| Cyclin D1 | 102 | 53 (52) | 49 (48) |
| VEGFR-2 | 95 | 44 (46.3) | 51 (53.7) |
| Phospho-mTORSer2448 | 101 | 38 (37.6) | 63 (62.4) |
| VEGF-A | 100 | 36 (36) | 64 (64) |
| p16 | 105 | 5 (4.8) | 100 (95.2) |
Krikelis et al. BMC Clinical Pathology 2013 13:1 doi:10.1186/1472-6890-13-1
